top of page

Ochre Bio CEO Jack O'Meara discusses his company's focus on liver diseases and its recent Boehringer Ingelheim partnership

Jack O'Meara describes Ochre's unique preclinical testing strategy as it develops siRNA drugs for liver diseases, and he touches on a high profile partnership the company signed in recent weeks.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page